However, CMS clarified in a memo dated March 20, 2024, that anti-obesity medications that receive FDA approval for an additional medically accepted indication can be considered a Part D drug for that specific use. As of August 19, 2024, the only GLP-1 RA this applies to is Wegovy, which, in addition to its obesity indication, is also indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight
Prices are as follows
Clinical Symptoms in Infants Perinatal symptoms include decreased fetal movements, polyhydramnios, and growth restriction
These include a reduced calorie diet, increased physical activity and, ideally, 7-9 hours sleep a night
It appears to support healthy blood lipids and cholesterol too